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K e y  M e s s a g e 
A commensal bacterial strain was engineered to 
express and secret antiviral peptide against influenza 
A virus.
A bioshield against influenza virus infection by 
commensal bacteria secreting antiviral peptide
JD Huang *, BJ Zheng, KY Yuen
Introduction
Avian influenza is caused by influenza viruses such 
as the influenza A virus. In 1997 in Hong Kong, 
the avian influenza viruses were found to cross the 
species barrier to infect human beings and cause 
respiratory illness and death. H5N1 viruses later re-
emerged in Asia with human cases of infection, of 
which more than 50% were fatal. 
 We proposed to genetically engineer naturally 
occurring bacteria to provide protection against 
influenza A virus infection by secreting a peptide that 
interferes with viral attachment. Introduction and 
colonisation of these genetically modified bacteria in 
the oral mucosa and respiratory tract would provide 
a natural bioshield for uninfected individuals and 
protection against influenza A virus. 
Methods
This study was conducted from December 2008 to 
May 2011. In order for the bioshield to be successful, 
there should be (1) continuous expression and 
secretion of a potent antiviral peptide at a high level; 
(2) colonisation of the genetically modified microbes 
on the mucosal surface of the respiratory tract for 
prolonged periods to block infection by influenza 
A virus; and (3) no pathology in the colonised 
host caused by the genetically engineered bacteria. 
Similar strategies have been used to protect animals 
against HIV,1 Candida albicans,2 and Streptococcus 
mutans.3 The technology and ‘bio-bricks’ necessary 
for building an anti-H5N1 bacterium strain are all 
available as follows:
 (1) Bacterial strains that colonise the 
respiratory tract: unlike immunisation in which 
the bacteria need to exist only for a limited period, 
antiviral peptide has to be present continuously in 
the secretions of the upper airway when the patient 
is challenged by the influenza virus. This can only 
happen if the bacteria producing the antiviral peptide 
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form a normal commensal bacterial strain that has 
a survival advantage in the pharynx. Gram-positive 
bacteria such as Streptococcus and Lactobacilli have 
a distinct advantage. Streptococcus gordonii has 
the best track record.4 S gordonii is a commensal 
bacterium commonly found on healthy human oral 
mucosa, the upper respiratory tract, and in dental 
plaque with a high colonising ability. Although 
associated with dental caries, it is less virulent than 
Streptococcus mutans but does not lose the ability 
to colonise the oropharynx continuously. It forms 
commensal microflora in humans without causing 
any pathology.  
 (2) Peptide with anti-influenza virus function: 
a 20-amino-acid peptide derived from the signal 
sequence of fibroblast growth factor 4 has exhibited 
broad-spectrum antiviral activity against influenza 
viruses including the highly pathogenic H5N1 
subtype.5 This peptide prevents viral infection by 
binding to the viral haemagglutinin protein to block 
attachment of the virus to the cellular receptor in 
vivo and in vitro. A 100% survival was observed 
when BALB/c mice were infected with H5N1 
A/Hong Kong/156/97 strain pre-treated with 2 
mM of this peptide. In addition to the preventive 
effect, this peptide showed promising therapeutic 
value. When BALB/c mice were first infected with 
A/Hong Kong/156/97 and then given 2 mM of the 
peptide intranasally, there was 100% survival at 7 
dpi, compared with 0% survival without treatment. 
Importantly, mice that received this peptide alone 
exhibited no toxicity.5
 In this project, the pLEX secreting expression 
system was first tested with green fluorescent 
protein (GFP). Then an antiviral peptide gene was 
cloned into the pLEX vector, transforming the 
resulting plasmid into S gordonii. The expression 
and secretion of antiviral peptide in the culture 
supernatant was examined by western blot and 
dot blot. The protective function of the peptide 
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was evaluated in vitro by the haemagglutination 
inhibition (HI) assay. To verify the protection in vivo, 
mice were challenged with lethal influenza virus in 
the presence or absence of the engineered bacteria.
Results
The efficiency of pLEX expression system in S gordonii 
GP204 stain was verified by GFP report protein (Figs 1 
and 2). Nevertheless, the expression and secretion of 
the target antiviral peptide (EB) could not be detected 
in the supernatant of S gordonii GP204 culture 
by western blot or dot blot. Therefore, a series of 
pLEX-xEB clones was constructed to optimise 
expression. With the optimised EB expression 
system, secreted EB still could not be detected by 
western blot in the supernatant. The protective effect 
of EB expression was evaluated in vitro using HI 
assay. EB peptides had been secreted into the culture 
supernatant. The secreted EB blocked influenza 
virus and inhibited binding of the influenza virus to 
turkey red blood cells (Fig 3). 
 The protective effect of EB-expressing 
S gordonii against influenza virus in mice was 
evaluated. First, the colonisation of S gordonii in 
mice was evaluated. Four weeks after inoculation, 
75% of mice were still colonised with S gordonii. To 
evaluate the protective effect, mice colonised with 
S gordonii were challenged with lethal influenza 
virus. There was no significant difference in survival 
rate between the group colonised with S gordonii 
harbouring pLEX-4EB and the control group. Further 
optimisation strategies of the expression system for 
increasing EB expression in vivo are necessary.
Discussion
S gordonii GP204 has been extensively studied and 
used to surface display or secrete various functional 
proteins.6 We successfully verified the efficiency of 
the pLEX expression system in S gordonii GP204 
stain by GFP reporter protein. Nevertheless, when 
detecting EB expression in S gordonii GP204, there 
were unexpected difficulties. Unlike GFP protein, in 
the supernatant and cells of recombinant bacteria, 
EB expression could not be detected by western blot 
or dot blot. This might have been because: (1) EB 
expression was too low to be detected. It is possible 
that the promoter activity of gtfG in pLEX may be 
insufficient to secrete detectable amounts of small 
peptide. (2) Detection method was inappropriate. 
The dot-blot or western blot assay may not be 
sensitive enough to detect such a small peptide 
(~2 kDa). (3) It is possible that only relatively 
large proteins can be secreted in this system; it is 
FIG 1.  Construction of pLEX1.4a/1.6-GFP
FIG 2.  (a) Verification of transformation by bacteria liquid PCR: 1 denotes culture of pLEX1.4a-GFP transformed S gordonii 
GP204, 2 Culture of pLEX1.6-GFP transformed S gordonii GP204, 3 culture of blank S gordonii GP204 as negative control, 4 
pLEX1.6 plasmid as negative control, and 5 pLEX1.6-GFP plasmid as positive control. (b) Verification of GFP expression in 
culture supernatant and cells by western blot: 1 denotes cell l of 7207-GFP as positive control, 2 supernatant of S gordonii GP204 
transformed with pLEX1.4a-GFP, 3 supernatant of S gordonii GP204 transformed with pLEX1.6-GFP, 4 supernatant of blank 
S gordonii GP204 as negative control, 5 cells of S gordonii GP204 transformed with pLEX1.4a-GFP, 6 cells of S gordonii GP204 
transformed with pLEX1.6-GFP, and 7 cells of blank S gordonii GP204 as negative control.
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not known if small peptides (ie 20 aa) can also be 
secreted by this strategy. 
 Therefore, our optimisation strategy was to 
multiply the sequence of EB. We constructed a series 
of pLEX-xEB-his clones to optimise the secreting 
expression. Likewise, western blot results detected 
no EB-his expression in culture supernatant. We then 
decided to detect the presence of EB by its protective 
function. This was performed in vitro by HI assay. 
The HI assay result indicated that EB peptides were 
likely secreted into the culture supernatant, as only 
the bacteria harbouring EB expressing plasmids 
can block influenza virus and inhibited influenza 
virus from binding to turkey red blood cells. The 
bacteria that contained the empty vector failed to 
block viral binding. Hence, we further evaluated the 
protection against influenza virus in mice. There was 
no significant difference in survival rate between 
the pLEX-4EB group and GP204 control group. We 
suspect that the expression of antiviral peptide was 
too low to completely block the influenza virus. It is 
possible that the amount of inoculated bacteria that 
could secrete antiviral peptide was insufficient, or 
that the efficiency of the pLEX system in vivo was 
not as high as necessary. Another possible reason 
was that EB peptides might have been broken down 
by S gordonii. A minimal and optimal sequence 
of EB peptide has been reported to improve the 
antiviral efficacy and decrease the synthesis costs.7 
Nonetheless, it is unknown whether this minimal 
epitope will be better expressed in S gordonii. It is 
also very difficult to detect and evaluate the secreting 
expression of small epitopes in the supernatant. 
Although EB is not toxic to either HeLa or Vero 
cells at 100 μM, toxicity of the peptide to S gordonii 
cannot be excluded. In future, we will commercially 
synthesise EB peptide and evaluate its toxicity at 
various concentrations with S gordonii.
 Overall, we successfully verified the efficiency 
of pLEX expression system in S gordonii GP204 stain 
by GFP reporter protein and constructed a series of 
engineered commensal bacteria strains. Nonetheless, 
to build an effective anti-influenza bioshield, there 
remain a few hurdles to be overcome: (1) It is 
difficult to obtain high level secreting expression of 
EB peptide both in vivo and in vitro thus resulting in 
no effective protection. (2) The plasmid containing 
the EB peptide sequence is unstable and can be 
easily lost in vivo and may contribute to low peptide 
expression. (3) S gordonii colonisation in mice is not 
stable and needs multiple inoculations supplied with 
appropriate antibiotics.
 Although the challenge experiments did not 
provide efficient protection, the supernatant of 
the engineered bacteria did show evidence of viral 
inhibition. This offers hope that the strategy may 
work by improving the expression and colonisation 
efficiency. If successful, the novel bioshield can be 
inoculated by simple combination with nutritious 
foods or encapsulated. This will be more convenient 
and acceptable to use, and easier to administer. The 
bioshield can be self-administered and eliminates 
the use of a hypodermic needle. A bioshield against 
avian influenza viruses is easy to manufacture.
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FIG 3.  Haemagglutination inhibition assay 
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